The return of EO9: A bioreductive indoloquinone targeted at bladder cancer

被引：0
|
作者：
Phillips, RM [1 ]
机构：
[1] Inst Canc Therapeut, Bradford, W Yorkshire, England
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [31] Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates
    Jain, Arun
    Phillips, Roger M.
    Scally, Andrew J.
    Lenaz, Gino
    Beer, Mario
    Puri, Rajiv
    UROLOGY, 2009, 73 (05) : 1083 - 1086
  • [32] The bromoquinone annulation reaction: a formal total synthesis of EO9
    Comer, E
    Murphy, WS
    ARKIVOC, 2003, : 286 - 296
  • [33] EO9 (Apaziquone): from the clinic to the laboratory and back again
    Phillips, Roger M.
    Hendriks, Hans R.
    Peters, Godefridus J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2013, 168 (01) : 11 - 18
  • [34] Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity
    Samuni, AM
    DeGraff, W
    Krishna, MC
    Mitchell, JB
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2002, 234 (01) : 327 - 333
  • [35] A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG)
    Pavlidis, N
    Hanauske, AR
    Gamucci, T
    Smyth, J
    Lehnert, M
    teVelde, A
    Lan, J
    Verweij, J
    ANNALS OF ONCOLOGY, 1996, 7 (05) : 529 - 531
  • [36] Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity
    Ayelet M. Samuni
    William DeGraff
    Murali C. Krishna
    James B. Mitchell
    Molecular and Cellular Biochemistry, 2002, 234-235 : 327 - 333
  • [37] Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9
    SM Bailey
    MD Wyatt
    F Friedlos
    JA Hartley
    RJ Knox
    AD Lewis
    P Workman
    British Journal of Cancer, 1997, 76 : 1596 - 1603
  • [38] Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle
    Sabien C. van der Schoot
    Bastiaan Nuijen
    Frits M. Flesch
    Ashok Gore
    Dorla Mirejovsky
    Luigi Lenaz
    Jos H. Beijnen
    AAPS PharmSciTech, 8 (3)
  • [39] Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle
    van der Schoot, Sabien C.
    Nuijen, Bastiaan
    Flesch, Frits M.
    Gore, Ashok
    Mirejovsky, Dorla
    Lenaz, Luigi
    Beijnen, Jos H.
    AAPS PHARMSCITECH, 2007, 8 (03):
  • [40] Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9
    Bailey, SM
    Wyatt, MD
    Friedlos, F
    Hartley, JA
    Knox, RJ
    Lewis, AD
    Workman, P
    BRITISH JOURNAL OF CANCER, 1997, 76 (12) : 1596 - 1603
12345